Observational studyDigestive diseases and sciences2025
Mirikizumab in the Treatment of Ulcerative Colitis: Initial Real-World Data in a Population from a Large Tertiary Center.
Observational study in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Real-world effectiveness and predictors of need for extended induction of mirikizumab therapy in ulcerative colitis.Journal of the Canadian Association of Gastroenterology · 2026Article
- Mirikizumab is equally effective in ustekinumab-exposed and ustekinumab-naïve patients with UC: a multicenter real-world cohort.Crohn's & colitis 360 · 2026Article
- Highlights of the 2026 European Crohn's and Colitis Conference: redefining the IBD care continuum.Crohn's & colitis 360 · 2026Review
- Induction and Prolonged Induction With Mirikizumab in Ulcerative Colitis-A Prospective, Real-World Study From the Sicilian Network for Inflammatory Bowel Disease (SN-IBD).United European gastroenterology journal · 2026Article
- Comparative effectiveness of mirikizumab and risankizumab in patients with ulcerative colitis: A propensity-matched cohort study.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Article
- Effectiveness and safety of mirikizumab in ulcerative colitis: real-world data from the Latium Net.BMJ open gastroenterology · 2026Article
- Interleukin-23 Inhibitors in Inflammatory Bowel Disease.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Interleukin-23p19 Inhibitors in Inflammatory Bowel Disease: From Current Insights to Future Directions.Journal of personalized medicine · 2026Review
- Challenges and Treatment Strategies in Elderly Patients with Inflammatory Bowel Disease: A Systematic Review and Narrative Synthesis.Journal of personalized medicine · 2026Review
- Targeting IL-23p19 in Inflammatory Bowel Disease: The Road Ahead.Journal of inflammation research · 2026Review
- Efficacy of Biologic Agents and Small Molecules for Endoscopic Improvement and Mucosal Healing in Patients with Moderate-to-Severe Ulcerative Colitis: Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Interleukin 23: Pathogenetic Involvement and Therapeutic Target for Ulcerative Colitis.Journal of clinical medicine · 2025Review
- Mirikizumab for Ulcerative Colitis: A Game-Changer or Just Another Incremental Advance?Digestive diseases and sciences · 2025Article
- Mirikizumab in ulcerative colitis: real-world evidence from an international two-center retrospective cohort study.Therapeutic advances in gastroenterology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMirikizumab, an anti-p19IL-23 monoclonal antibody, has shown efficacy and safety in treating moderately to severely active ulcerative colitis (UC) in clinical trials. We assessed the effectiveness and safety of mirikizumab for the treatment of UC in a real-world setting.
methodsWe conducted a prospective observational study of adult patients with UC who were started on mirikizumab for active disease between January 1, 2024, and April 30, 2024. Clinical, biochemical, sonographic, and endoscopic data were collected. The primary outcome was clinical response and remission at 12 weeks, and secondary outcomes included corticosteroid-free remission (CSFR) and biochemical marker improvement at week 12. Adverse events were recorded.
resultsTwenty-two patients were initiated on mirikizumab during the study period, with 20 included in the analysis. The majority were female (65%) and had a median duration of disease of 12 years (IQR 8.0-18.5]. The majority of patients had previously been exposed to three or more advanced therapies (70% of patients) prior to mirikizumab start. Clinical remission (SCCAI < 3) increased from 30% at baseline to 83% at week 12. CSFR increased from 15% at baseline to 78% at week 12. Median SCCAI scores significantly decreased from 3.5 at baseline to 0.5 at week 12 (p < 0.001), driven primarily by an improvement in general well-being and a decrease in urgency. Adverse effects were mild to moderate, with one serious event of streptococcal pharyngitis.
conclusionMirikizumab demonstrated significant clinical effectiveness in achieving clinical remission, response, and CSFR in patients with UC.
Indexed as
Identifiers
40048134What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.